FY2029 Earnings Forecast for NTLA Issued By William Blair

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Research analysts at William Blair issued their FY2029 earnings estimates for shares of Intellia Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Minter expects that the company will earn $2.96 per share for the year. William Blair has a “Neutral” rating and a $14.00 price objective on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

NTLA has been the subject of a number of other reports. Citigroup upped their price objective on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Barclays reduced their price objective on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. BMO Capital Markets reduced their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Finally, Oppenheimer reduced their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $9.10 on Monday. Intellia Therapeutics has a 52-week low of $8.30 and a 52-week high of $32.42. The company has a 50-day simple moving average of $10.74 and a two-hundred day simple moving average of $15.36. The company has a market capitalization of $942.00 million, a price-to-earnings ratio of -1.67 and a beta of 1.97.

Insider Activity at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Polar Asset Management Partners Inc. lifted its stake in Intellia Therapeutics by 1,144.1% in the 4th quarter. Polar Asset Management Partners Inc. now owns 282,400 shares of the company’s stock worth $3,293,000 after purchasing an additional 259,700 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Intellia Therapeutics in the 4th quarter worth approximately $25,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Intellia Therapeutics by 5.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 483,185 shares of the company’s stock worth $5,634,000 after purchasing an additional 23,173 shares in the last quarter. Voloridge Investment Management LLC lifted its stake in Intellia Therapeutics by 226.8% in the 4th quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock worth $17,805,000 after purchasing an additional 1,059,751 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new stake in Intellia Therapeutics in the 4th quarter worth approximately $6,122,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.